Natalie Maimon Rabinovich

BRAF Mutant Lung Cancer: Programmed Death Ligand 1 Expression, Tumor Mutational Burden, Microsatellite Instability Status, and Response to Immune Check-Point Inhibitors

Elizabeth Dudnik, Nir Peled, Hovav Nechushtan et al. · Journal of Thoracic Oncology · 2018 · 220 citations · Full text

Medicine, Molecular Genetics, Oncology +14

Efficacy and Safety of <b><i>ALK</i></b> Tyrosine Kinase Inhibitors in Elderly Patients with Advanced <b><i>ALK</i></b>-Positive Non-Small Cell Lung Cancer: Findings from the Real-Life Cohort

Aseel Bedas, Nir Peled, Natalie Maimon Rabinovich et al. · Oncology Research and Treatment · 2019 · 17 citations · Full text

Medicine, Oncology, Pharmacology +17

Efficacy and Safety of BRAF Inhibitors With or Without MEK Inhibitors in BRAF-Mutant Advanced Non–Small-Cell Lung Cancer: Findings From a Real-Life Cohort

Elizabeth Dudnik, Jair Bar, Nir Peled et al. · Clinical Lung Cancer · 2019 · 14 citations

Medicine, Oncology, Pharmacology +13

Efficacy of Pembrolizumab vs. Nivolumab Plus Ipilimumab in Metastatic NSCLC in Relation to PD-L1 and TMB Status

Walid Shalata, Natalie Maimon Rabinovich, Abed Agbarya et al. · Cancers · 2024 · 12 citations · Full text

Medicine, Oncology, Pharmacotherapy +17